88E retrieves excellent wireline data from Icewine#2

|

Published 22-MAY-2017 14:28 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

88 Energy (ASX:) announced on Monday that the company had completed wireline logging at its Icewine#2 project, located onshore North Slope of Alaska.

Management described the data quality as excellent, importantly complementing the core and logs retrieved at Icewine#1, which it hopes can be replicated from a production perspective.

Having achieved a positive outcome with wireline logging, the enhanced data suite will ensure optimal design of the planned stimulation program.

There was a hitch with the cementing of the 4.5 inch production liner, as hole conditions in the Pebble Shale Unit (beneath the HRZ production interval) prevented successful completion. However, management assured that this was a minor setback and had not altered the schedule for production testing, particularly given 88E is ahead of schedule on the project.

Hartleys analyst, Aiden Bradley examined 88 Energy’s (ASX:88E) prospects as the company prepared to execute its drilling campaign at Icewine#2.

He noted that based on the results of the Icewine#1 well, situated just 20 metres away, expectations are that this well will flow oil to surface in a range between 100 barrels of oil per day and 200 barrels of oil per day.

Bradley anticipates success would likely be sufficient to attract a major farm-in partner which would support the current valuation.

Despite recent weakness in the oil price and a lull in activity leading up to the drilling of Icewine#2, 88E has traded strongly in the last six months with its share price increasing 25% from 3.7 cents to an intraday high of 5 cents in early May.

It should be noted that broker projections and price targets as seen below are only estimates and may not be met. Also, share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

As can be seen in the following chart, 88E has substantially outperformed relative to the Nymex Oil (light sweet crude) price movements over the last six months.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

The fact that 88E has been able to hold around early May levels despite the subsequent downturn in the oil price suggests that investors are confident that Icewine#2 will deliver.

Bradley has a valuation of 7 cents on the stock, implying upside of 50% relative to Monday morning’s opening price of 4.7 cents.

tags

OIL


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X